KEYNOTE-522 Study of Pembro plus Chemo vs. Placebo plus Chemo as Neoadjuvant Treatment Followed by Pembro vs. Placebo as Adjuvant Treatment for Early TNBC: Pathologic Complete Response in Key Subgroups

被引：0
|
作者：
Schmid, P. [1 ]
机构：
[1] Barts Canc Inst, Ctr Expt Med, London, England
来源：
ANNALS OF SURGICAL ONCOLOGY | 2020年 / 27卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P38
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [1] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes, J.
    Dent, R.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Karantza, V.
    Zhao, J.
    Aktan, G.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 853 - 854
  • [2] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
    Schmid, Peter
    Cortes, Javier
    Bergh, Jonas C. S.
    Pusztai, Lajos
    Denkert, Carsten
    Verma, Sunil
    McArthur, Heather L.
    Kummel, Sherko
    Ding, Yu
    Karantza, Vassiliki
    Dang, Thao
    Dent, Rebecca Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] KEYNOTE-522: Phase III study of pembrolizumab (pembro) 1 chemotherapy (chemo) vs placebo 1 chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes Castan, J.
    Bergh, J.
    Pusztai, L.
    Denkert, C.
    Verma, S.
    McArthur, H. L.
    Zhao, J.
    Aktan, G.
    Dang, T.
    Dent, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
    Dent, R.
    Cortes, J.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Jensen, E.
    Karantza, V.
    Aktan, G.
    O'Shaughnessy, J.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1241 - S1242
  • [5] Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
    Kuemmel, S.
    Schmid, P.
    Harbeck, N.
    Takahashi, M.
    Untch, M.
    Boileau, J. -F.
    Cortes, J.
    McArthur, H.
    Dent, R.
    O'Shaughnessy, J.
    Pusztai, L.
    Foukakis, T.
    Park, Y. H.
    Hui, R.
    Cardoso, F.
    Denkert, C.
    Zhu, Y.
    Pan, W.
    Karantza, V.
    Fasching, P.
    BREAST, 2023, 68 : S63 - S64
  • [6] HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
    Dent, R. A.
    Cortes, J.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Untch, M.
    Fasching, P. A.
    Cardoso, F.
    Haiderali, A.
    Jia, L.
    Nguyen, A. M.
    Pan, W.
    O'Shaughnessy, J.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S600 - S601
  • [7] Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study
    Kuemmel, Sherko
    Schmid, Peter
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Boileau, Jean-Francois
    Cortes, Javier
    McArthur, Heather
    Dent, Rebecca
    O'Shaughnessy, Joyce
    Pusztai, Lajos
    Foukakis, Theodoros
    Park, Yeon Hee
    Hui, Rina
    Cardoso, Fatima
    Denkert, Carsten
    Zhu, Yalin
    Pan, Wilbur
    Karantza, Vassiliki
    Fasching, Peter A.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 2) : S295 - S296
  • [8] KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
    Schmid, P.
    Cortes, J.
    Dent, R.
    Pusztai, L.
    McArthur, H.
    Kummel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Untch, M.
    Fasching, P. A.
    Cardoso, F.
    Ding, Y.
    Tryfonidis, K.
    Aktan, G.
    Karantza, V.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1198 - 1200
  • [9] Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
    McArthur, Heather
    Cortes, Javier
    Dent, Rebecca
    O'Shaughnessy, Joyce
    Pusztai, Lajos
    Kuemmel, Sherko
    Foukakis, Theodoros
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Denkert, Carsten
    Zhu, Yalin
    Ding, Yu
    Pan, Wilbur
    Schmid, Peter
    CANCER RESEARCH, 2023, 83 (05)
  • [10] Neoadjuvant/adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585
    Shitara, Kohei
    Bang, Yung-Jue
    Wyrwicz, Lucjan S.
    Rha, Sun Young
    Oshima, Takashi
    Di Bartolomeo, Maria
    Park, Young-Kyu
    Lonardi, Sara
    Weber, Patricio Eduardo Yanez
    Yen, Chia-Jui
    Metges, Jean-Philippe
    Garrido, Marcelo
    Moehler, Markus H.
    Pelles-Avraham, Sharon
    Yong, Wei-Peng
    Spallanzani, Andrea
    Jensen, Erin
    Krishnan, Radha
    Shih, Chie-Schin
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345